TGFB1 and ovarian carcinoma: Inhibition of TGF-β signaling decreased vascular endothelial growth factor (VEGF) and IL-8 expression, key angiogenic and tumor growth factors in ovarian cancer [79,80], leading to reduced peritoneal tumor burden and restored diaphragm lymphatic vessel functionality, thereby reducing ascites accumulation.